Data backs Vasca's haemodialysis access system:
This article was originally published in Clinica
Executive Summary
Vasca says that a multicentre clinical study has shown that patients using its LifeSite haemodialysis access system experienced significantly fewer device-related adverse events and complications during a 12-month follow-up period than those using a standard haemodialysis catheter. Patients treated with the LifeSite system were also significantly more likely to still be using the device a year later than those using the standard catheter, says the Tewksbury, Massachusetts firm. The LifeSite device is a totally subcutaneous haemodialysis access system. It was cleared for sale in the US in 2000.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.